PRESS INFORMATION

Olympus Introduces New Surgical Energy Device THUNDERBEAT II for Hemostatic Cutting and Vessel Sealing

Tokyo and Hamburg, October 21, 2025 – Olympus Corporation (Olympus), a global MedTech company, today announced the launch of THUNDERBEAT II, the next generation hybrid energy device for soft tissue management in Europe, the Middle East and Africa (EMEA region). THUNDERBEAT II is designed to deliver faster, more hemostatic dissection and large vessel transection[1] in both laparoscopic and open surgery.

As part of Olympus' pioneering THUNDERBEAT line, THUNDERBEAT II builds on its predecessor with faster hemostatic dissection, more secure vessel sealing, and a refined probe design that minimizes thermal impact on surrounding tissue. The range of three energy modes—including a new ultrasonic energy setting—supports surgeons during technically challenging procedures, enabling them to adapt to changing clinical conditions without interrupting the procedure to exchange instruments. THUNDERBEAT II offers healthcare professionals greater versatility and even more features than ever before.

"Designed to support clinicians in complex surgical procedures, THUNDERBEAT II underscores Olympus' commitment to advancing hybrid energy technology," said Yannick Sieker, Senior Director & Business Unit Leader Surgery for Olympus EMEA. *"We are excited to complement our surgical energy portfolio with this innovative device, which aims to address surgeons' needs and improve clinical outcomes."*

Delivering Enhanced Versatility and Thermal Control

THUNDERBEAT II features three output modes: hybrid energy (SEAL & CUT Mode) for faster, more precise hemostatic dissection compared to its previous model; advanced bipolar energy (SEAL Mode) for vessel pre-sealing and spot hemostasis; and newly added ultrasonic energy (ULTRASONIC Mode) for fine dissection in anatomical spaces where cutting without bipolar energy is required.

The refined slim probe and jaw of THUNDERBEAT II supports accurate and fine dissection while minimizing impact on surrounding tissue. In addition, the newly developed thermal shield at the distal tip slows heat transfer from

1. Up to 7 mm.

the probe to the exterior surface of the jaw, reducing the risk of unintended heat damage to surrounding tissues and vessels. The device also introduces an improved ergonomic handle, reducing the required closing force, and a cordless transducer that relocates the cable—all designed to enhance freedom of movement and comfort for surgeons throughout the procedure.

THUNDERBEAT II is now commercially available in the EMEA region, further strengthening Olympus' portfolio of surgical energy devices. A subsequent launch in Japan is planned for later this year, with a global rollout to follow, pending regulatory approvals including product registration and market clearance.

About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Olympus Europa, headquartered in Hamburg, Germany, serves the EMEA (Europe, Middle East, Africa) Region and employs 7,600 people in 29 countries. For more information, visit **www.olympus-europa.com** and follow our LinkedIn account: **linkedin.com/company/olympus-corp.**

For questions or additional information, please contact:

Matthias Gengenbach
Head of Corporate Communications EMEA
Olympus Europa SE & Co. KG
Tel.: +49 151 4236 9420
Email: **matthias.gengenbach@olympus.com**
www.olympus-europa.com